Pharmacy Week in Review: April 22, 2016

Imaging data from the CONTENTed study suggest the type 2 inflammation that drives severe asthma may affect more than the airways.

Renal benefit appeared only in patients with albuminuria in a 75,455-person BMJ analysis, while sulfonylureas signaled faster decline without it.

Authors of a pharmacist-directed transitions of care study discuss what drives pneumococcal vaccine hesitancy and how pharmacists can build systematic vaccine screening into inpatient workflows.

HYPERION trial data now support sotatercept within a patient's first year of pulmonary arterial hypertension (PAH) diagnosis, cutting clinical worsening risk by 76% compared with placebo.

A stewardship program combining EHR alerts and pharmacist-led education offers a replicable model for reducing bleeding risk.

Tim Cernohous of Cencora explains why patient trust no longer guarantees satisfaction—and how automation and better communication can close the gap with mail order.

Eight Humira biosimilars have been launched, but payer formularies and interchangeability rules decide what dispenses.

At NEIAP 2026, Kelsey Norman, PharmD, walked through how VESALIUS-CV, Lp(a)HORIZON, and CKM guidelines change pharmacist-led lipid care.